Programming the immune checkpoint to treat hematologic malignancies

Medicine and Dentistry

• Combination Therapy 100%
• Hematologic Malignancy 60%
• Cancer 40%
• Monoclonal Antibody 20%
• Immune Response 20%
• Side Effect 20%
• Malignant Neoplasm 20%
• Adverse Event 20%
• Tumor Cell 20%
• Hodgkin's Lymphoma 20%
• Immune System 20%
• CTLA-4 20%
• Tumor Microenvironment 20%
• Development 20%
• Diffuse Large B-Cell Lymphoma 20%
• Immunological Tolerance 20%
• B-Cell Chronic Lymphocytic Leukemia 20%
• Follicular Lymphoma 20%
• Lymphosarcoma 20%
• Cells 20%
• Base 20%
• Therapeutic Procedure 20%
• Patient 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Immune Checkpoint Inhibitor 80%
• Hematologic Malignancy 60%
• Programmed Death-Ligand 1 40%
• Adverse Event 20%
• Monoclonal Antibody 20%
• Side Effect 20%
• Hodgkin Disease 20%
• Diffuse Large B Cell Lymphoma 20%
• Malignant Neoplasm 20%
• Follicular Lymphoma 20%
• Chronic Lymphatic Leukemia 20%
• Cytotoxic T Lymphocyte Antigen 4 20%
• Tumor Microenvironment 20%
• Base 20%
• Lymphosarcoma 20%